⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10731011 | 0.79 | — | — | |
| SCHEMBL6976529 | 0.79 | — | — | |
| SCHEMBL6983191 | 0.76 | — | — | |
| SCHEMBL9863476 | 0.74 | GPR84 (0.57) | — | |
| SCHEMBL219520 | 0.70 | — | — | |
| SCHEMBL5403108 | 0.69 | — | — | |
| SCHEMBL2249193 | 0.67 | — | — | |
| SCHEMBL483277 | 0.67 | — | — | |
| Ethylene Glycol SCHEMBL22832170 | 0.67 | — | — | |
| SCHEMBL2327588 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023044462-A1 | CYSTEINE PROTEASE INHIBITOR FORMULATIONS AND METHOD OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-03-23 | — | — | WO | claimed |
| CN-111943560-B | Low-resilience alkali-free liquid accelerator and preparation method thereof | 武汉源锦建材科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-111943560-A | Low-resilience alkali-free liquid accelerator and preparation method thereof | 武汉源锦建材科技有限公司 | 2020-11-17 | — | — | CN | claimed |
| EP-0682945-B1 | Oral sustained release preparation | LANNACHER HEILMITTEL (AT) | 1999-06-09 | — | — | EP | claimed |
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023044462-A1 | CYSTEINE PROTEASE INHIBITOR FORMULATIONS AND METHOD OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| CN-114988756-B | Underwater anti-dispersion expanding agent and preparation method thereof | 江苏申御特种建材有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-113277807-B | Super-retarding concrete for pile foundation and preparation method thereof | 北京建工新型建材有限责任公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-111943560-B | Low-resilience alkali-free liquid accelerator and preparation method thereof | 武汉源锦建材科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-114988756-A | Underwater anti-dispersion expanding agent and preparation method thereof | 江苏申御特种建材有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113277807-A | Super-retarding concrete for pile foundation and preparation method thereof | 北京建工新型建材有限责任公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-111943560-A | Low-resilience alkali-free liquid accelerator and preparation method thereof | 武汉源锦建材科技有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-20020068238-A1 | Positive-working photoresist composition | TOKYO OHKA KOGYO CO., LTD. (JP) | 2002-06-06 | — | — | US | disclosed |
| CN-1309561-A | Therapeutic agent for erectile dysfunction | MOCHIDA PHARM CO LTD (JP) | 2001-08-22 | — | — | CN | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| CN-1284075-A | Novel compounds having CGMP-PDE inhibitory effect | MOCHIDA PHARM CO LTD (JP) | 2001-02-14 | — | — | CN | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |